Doctor taking notes

Resources

Publications

Nov 2019
Safety and Efficacy of DUR-928: A Potential New Therapy for Acute Alcoholic Hepatitis 
Tarek Hassanein, Lance L Stein, Steven L Flamm, Paul Martin, Matthew C. Cave, Christina Blevins, Deborah Scott, William Krebs, and WeiQi Lin | American Association for the Study of Liver Diseases (AASLD) The Liver Meeting
Apr 2019
Pharmacokinetic and Pharmacodynamic Response in Individual NASH Patients Receiving Two Dose Levels of DUR-928 
Jaymin Shah, Dave Ellis, William Kemp, Jim Brown, and WeiQi Lin | NASH Summit
Nov 2018
A 14-Day Intravenous Infusion Toxicity and Toxicokinetic Study of DUR-928, a Novel, First in Class, Investigational Therapeutic in Sprague-Dawley Rats 
Linval DePass, Andrew Miksztal, Ethan Bui, Hongwei Wu, Cedric Gordon, and WeiQi Lin | American College of Toxicology
Oct 2018
Safety and Single Ascending Dose Pharmacokinetic Study of DUR-928 in Patients with Chronic Kidney Disease versus Matched Control Subjects
Jaymin Shah, Dave Ellis, Andrew Miksztal, and WeiQi Lin | American Society of Nephrology annual Kidney Week meeting
Oct 2018
Attenuation of Renal Ischemic Reperfusion Injury in Rats with DUR-928, a Novel, First-in-Class Therapeutic in Development for Renal Disease 
Mee J. Kim, Hongwei Wu, and WeiQi Lin | American Society of Nephrology annual Kidney Week meeting

Factsheets

See the resources included here for more information and resources from DURECT.

In the News

No Results Found
Scroll to Top